Hope for RP in Herbal Remedy

Article

Patients with the hereditary degenerative eye disease retinitis pigmentosa (RP) may delay their loss of daytime vision by taking a traditional Chinese plant remedy Lycium barbarum also known as goji berry or wolfberry.

Patients with the hereditary degenerative eye disease retinitis pigmentosa (RP) may delay their loss of daytime vision by taking a traditional Chinese plant remedy Lycium barbarum also known as goji berry or wolfberry, a team from Hong Kong reports.

In an abstract presented May 1 at the 2016 ARVO conference in Seattle, WA, Henry Chan and colleagues from the Hong Kong Polytechnic University, Hong Kong studied 23 patients who got either the remedy or placebo daily for 12 months.

They found the group that got Lycium barbarum (LB) showed less deterioration in contrast visual acuity as measured by several tests.

“Our results confirm that the 6 months LB treatment for RP patients had marginal significant improvement

in low-contrast VA and central visual sensitivity," the team said.

The plant has a neuroprotective effect believed to delay or minimize the deterioration of central visual function in RP,” they concluded..

Those visual acuity measurements showed that changes of 10% contrast visual acuity for the groups were -0.5 for the LB

group and 0.6 for the placebo group.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.